Skip to main content
OpenTrials

Clinical trial condition

Retroviridae Infections

Explore clinical trials studying Retroviridae Infections. Study availability and eligibility vary by location and protocol.

5,663 public trials 308 recruiting studies
Refine in advanced search Browse all conditions

Retroviridae Infections trial results

Completed

Study of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV Drugs

NCT00002240

Conditions
Blood-Borne Infections, Communicable Diseases, Genital Diseases, +11 more
Locations
  • Clinsites / Sorra Research Ctr Birmingham, Alabama, United States
  • Univ of Alabama at Birmingham Birmingham, Alabama, United States
  • UCSD Treatment Ctr San Diego, California, United States
  • UCSF - San Francisco Gen Hosp San Francisco, California, United States
View all 17 locations
View Trial Details
Completed

The Safety and Effectiveness of Lamivudine Plus Stavudine or Zidovudine in HIV-Infected Patients Who Have Taken Zidovudine

NCT00002371

Conditions
Blood-Borne Infections, Communicable Diseases, Genital Diseases, +11 more
Locations
  • Harbor UCLA Med Ctr Torrance, California, United States
  • Univ of South Florida Tampa, Florida, United States
  • SUNY at Stony Brook / Division of Infectious Diseases Stony Brook, New York, United States
  • Houston Clinical Research Network / Div of Montrose Clinic Houston, Texas, United States
View Trial Details
Completed

Evaluation of an Anti-HIV Drug Combination That Includes a Coated Form of Didanosine (ddI EC) Compared to a Typical Anti-HIV Drug Regimen

NCT00002429

Conditions
Blood-Borne Infections, Communicable Diseases, Genital Diseases, +11 more
Locations
  • Sorra Research Ctr / Med Forum Birmingham, Alabama, United States
  • Body Positive Phoenix, Arizona, United States
  • AIDS Healthcare Foundation Los Angeles, California, United States
  • San Francisco Gen Hosp San Francisco, California, United States
View all 23 locations
View Trial Details
Completed

Safety and Effectiveness of a New Protease Inhibitor, BMS-232632, in HIV-Positive Patients Who Have Received Previous Treatment

NCT00004584

Conditions
Blood-Borne Infections, Communicable Diseases, Genital Diseases, +11 more
Locations
  • Sorra Research Ctr / Med Forum Birmingham, Alabama, United States
  • AIDS Healthcare Foundation Los Angeles, California, United States
  • Robert Scott MD Oakland, California, United States
  • Univ of California - Davis Med Ctr / CARES Sacramento, California, United States
View all 38 locations
View Trial Details
Completed

A Comparison of BMS-232632 With Efavirenz, Each in Combination With Zidovudine-Lamivudine

NCT00013897

Conditions
Blood-Borne Infections, Communicable Diseases, Genital Diseases, +11 more
Locations
  • Phoenix Body Positive Phoenix, Arizona, United States
  • Univ of Southern California Los Angeles, California, United States
  • Saint Francis Mem Hosp / HIV Care Unit San Francisco, California, United States
  • Dupont Circle Physicians Group Washington D.C., District of Columbia, United States
View all 99 locations
View Trial Details
Completed

Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy

NCT00246610

Conditions
Blood-Borne Infections, Communicable Diseases, Genital Diseases, +12 more
Locations
  • Pfizer Investigational Site Jacksonville, Florida, United States
  • Pfizer Investigational Site Miami, Florida, United States
  • Pfizer Investigational Site Metairie, Louisiana, United States
  • Pfizer Investigational Site Detroit, Michigan, United States
View Trial Details
Completed

DART II - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy

NCT00116116

Conditions
AIDS, Acquired Immunodeficiency Syndrome, Blood-Borne Infections, +14 more
Locations
  • Local Institution Bakersfield, California, United States
  • Local Institution San Francisco, California, United States
  • Local Institution Washington D.C., District of Columbia, United States
  • Local Institution Fort Lauderdale, Florida, United States
View Trial Details
Completed

Switching HIV-1 Infected Subjects From a Highly Active Anti-Retroviral Treatment (HAART) Regimen Dosed Twice Daily or More Frequently to a Once-Daily Regimen

NCT00135369

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +13 more
Locations
  • Local Institution Hobson City, Alabama, United States
  • Local Institution Montgomery, Alabama, United States
  • Local Institution Phoenix, Arizona, United States
  • Local Institution Little Rock, Arkansas, United States
View all 47 locations
View Trial Details

Related conditions